PCa Commentary | Volume 203 – July 2025
Edward Weber, MD, discusses the investigation of PROTACs (Proteolysis Targeting Chimeras) as a potential treatment for prostate cancer.
Read More
Journal Issue
PCa Commentary | Volume 202 – June 2025
Edward Weber, MD, discusses the PSMAfore protocol, moving the option of using [177Lu]-PSMA-617 front-forward in early progressive metastatic castration-resistant prostate cancer (mCRPC).
Read More
PCa Commentary | Volume 200 – April 2025
Edward Weber, MD, discusses radiation therapy is an option for treating localized prostate cancer. For selected men, it can preserve the quality of life. In men with small, localized lesions, it may be an option between whole gland therapy and active surveillance.
Read More
PCa Commentary | Volume 201 – May 2025
Dr. Weber discusses transdermal estradiol (tE2) in therapy for both non-metastatic and metastatic prostate cancer in comparison to conventional Lupron or Lupron+ARSI, offering new options for prostate cancer management with an improved adverse effect profile.
Read More
PCa Commentary | Volume 198 – February 2025
Pluvicto was approved in March 2022 for therapy in men with heavily pretreated castration resistant metastatic prostate cancer, and since then, it has become a frequently prescribed life-prolonging treatment. Sartor et al., NEJM 2021, reported that the median imaging-based progression-free survival for 177Lu PSMA was 8.7 months vs. 3.4 for ADT alone, and the median overall survival was 15.3 months vs.11.3 for ADT. Quality of life was similar. Pluvicto is administered via a short IV infusion every 6 weeks for 4-6 cycles.
Read More